177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer

NCT06329830 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Funding for the study was withdrawn.

Conditions

Metastatic Prostate Cancer
Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer

Interventions

DRUG: 177Lu-PSMA-617
DRUG: Niraparib abiraterone acetate
DRUG: Prednisone

Sponsor

Baptist Health South Florida

Collaborators

[object Object]